Review
Open access
Jul 2026
Predictive biomarkers for immunotherapy response in renal cell carcinoma: why have they failed?
Current limitations in the development of consistent predictive biomarkers are outlined and future progress will require biomarker-stratified prospective trial designs with prespecified endpoints and rigorous external validation to establish clinically meaningful biomarkers.
Felix Lübbersmeyer, V. Schuettfort, Margit Fisch et al.
· Current Opinion in Urology · 0 citations